ID   S462
AC   CVCL_1Y70
SY   Patient 6 cell line
DR   EFO; EFO_0006292
DR   cancercelllines; CVCL_1Y70
DR   Cosmic; 1132062
DR   Cosmic; 1801809
DR   DepMap; ACH-002693
DR   Millipore; SCC414
DR   Wikidata; Q54951928
RX   PubMed=15207265;
RX   PubMed=15735744;
RX   PubMed=18650488;
RX   PubMed=21084276;
RX   PubMed=21695156;
RX   PubMed=23437333;
RX   PubMed=28556483;
RX   PubMed=32642732;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~16 hours (PubMed=21084276).
CC   Sequence variation: Gene deletion; HGNC; HGNC:7765; NF1; Zygosity=Heterozygous (PubMed=15207265).
CC   Sequence variation: Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Heterozygous (PubMed=15207265).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; p.Tyr2285Ter (c.6792C>A); ClinVar=VCV000185082; Zygosity=Heterozygous (PubMed=15207265; DepMap=ACH-002693).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg110Pro (c.329G>C); ClinVar=VCV000233627; Zygosity=Heterozygous (PubMed=21084276; DepMap=ACH-002693).
CC   Derived from site: In situ; Thigh; UBERON=UBERON_0000376.
ST   Source(s): Millipore=SCC414; PubMed=28556483
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 12
ST   D16S539: 13
ST   D18S51: 16
ST   D19S433: 14
ST   D21S11: 29,31
ST   D2S1338: 23
ST   D3S1358: 14,17
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 10,12
ST   FGA: 20
ST   Penta D: 9,11
ST   Penta E: 11
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C3798; Malignant peripheral nerve sheath tumor
DI   NCIt; C3273; Neurofibromatosis type 1
DI   ORDO; Orphanet_3148; Malignant peripheral nerve sheath tumor
DI   ORDO; Orphanet_636; Neurofibromatosis type 1
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   19Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 19-12-24; Version: 15
//
RX   PubMed=15207265; DOI=10.1016/j.nbd.2004.01.006;
RA   Frahm S., Mautner V.-F., Brems H., Legius E., Debiec-Rychter M.,
RA   Friedrich R.E., Knoefel W.T., Peiper M., Kluwe L.;
RT   "Genetic and phenotypic characterization of tumor cells derived from
RT   malignant peripheral nerve sheath tumors of neurofibromatosis type 1
RT   patients.";
RL   Neurobiol. Dis. 16:85-91(2004).
//
RX   PubMed=15735744; DOI=10.1038/sj.onc.1208425;
RA   Mashour G.A., Drissel S.N., Frahm S., Farassati F., Martuza R.L.,
RA   Mautner V.-F., Kindler-Rohrborn A., Kurtz A.;
RT   "Differential modulation of malignant peripheral nerve sheath tumor
RT   growth by omega-3 and omega-6 fatty acids.";
RL   Oncogene 24:2367-2374(2005).
//
RX   PubMed=18650488; DOI=10.1215/15228517-2008-053; PMCID=PMC2719009;
RA   Holtkamp N., Malzer E., Zietsch J., Okuducu A.F., Mucha J., Mawrin C.,
RA   Mautner V.-F., Schildhaus H.-U., von Deimling A.;
RT   "EGFR and erbB2 in malignant peripheral nerve sheath tumors and
RT   implications for targeted therapy.";
RL   Neuro-oncol. 10:946-957(2008).
//
RX   PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799; PMCID=PMC3064267;
RA   Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R.,
RA   Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J.,
RA   Lev D.C.;
RT   "Autophagic survival in resistance to histone deacetylase inhibitors:
RT   novel strategies to treat malignant peripheral nerve sheath tumors.";
RL   Cancer Res. 71:185-196(2011).
//
RX   PubMed=21695156; DOI=10.1371/journal.pone.0021099; PMCID=PMC3113907;
RA   Spyra M., Kluwe L., Hagel C., Nguyen R., Panse J., Kurtz A.,
RA   Mautner V.-F., Rabkin S.D., Demestre M.;
RT   "Cancer stem cell-like cells derived from malignant peripheral nerve
RT   sheath tumors.";
RL   PLoS ONE 6:E21099-E21099(2011).
//
RX   PubMed=23437333; DOI=10.1371/journal.pone.0057152; PMCID=PMC3578816;
RA   Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L.,
RA   Mautner V.-F., von Deimling A.;
RT   "Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL
RT   is augmented by loss of NF1 through modulation of MYC/MAD and is
RT   potentiated by curcumin through induction of ROS.";
RL   PLoS ONE 8:E57152-E57152(2013).
//
RX   PubMed=28556483; DOI=10.1002/1878-0261.12086; PMCID=PMC5579334;
RA   Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H.,
RA   Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P.,
RA   Lothe R.A.;
RT   "Drug sensitivity and resistance testing identifies PLK1 inhibitors
RT   and gemcitabine as potent drugs for malignant peripheral nerve sheath
RT   tumors.";
RL   Mol. Oncol. 11:1156-1171(2017).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049; PMCID=PMC7317054;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:i50-i61(2020).
//